… does not require dosage adjustment, but pharmacokinetics has not been studied in patients
… 200 mg IV every 3 weeks or the investigator's choice of paclitaxel, docetaxel, or vinflunine. …

… Historically, treatment for patients with locally advanced and unresectable or metastatic
urothelial carcinoma with second-line, single-agent chemotherapy with taxanes or vinflunine has …

… receive iv EV on days 1, 8 and 15 of each 28-day cycle or either iv docetaxel, vinflunine
or … the safety, tolerability and pharmacokinetics of EV when administered iv to Japanese …

… Vinca alkaloid resistance in lung cancer (Zhang et al., 2017). Vinflunine, one of the initially
… cycle effects of two semisynthetic vinca alkaloids, vinflunine, and vinorelbine, in four human …

… Vinflunine, a dihydrofluoro semi-synthetic analog of vinorelbine, is used as the second line
of treatment in metastatic urothelial cancer. It … of vinca alkaloids, vinflunine also attaches to …

… Pharmacokinetic studies in patients with cancer have shown a triphasic serum decay pattern
following the rapid intravenous … Vinflunine displays a linear pharmacokinetic profile in the …

… vinflunine (VFN) (the fluorinated analogue of vinorelbine) (Figure 1). Since 2008, a novel
synthetic vinca alkaloid known as vinflunine … , pharmacology, pharmacokinetics, and toxicity, in …

… -line treatment was based on second-line CT (vinflunine or … , tolerability, and pharmacokinetics;
activity was evaluated as … among 112 patients treated with the recommended phase 2 …

… collected for pharmacokinetic and anti-… Phase III trial of vinflunine plus best supportive
care compared with best supportive care alone after a platinum-containing regimen in patients …

… Vinflunine is approved in Europe for second-line treatment of … Hepatic dysfunction or
obstructive liver disease increases … In a population pharmacokinetic study of ixabepilone as …